Distinguished in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Mark W. Kieran

Pediatric Hematology Oncology
44 Binney St, Room Sw331, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
44 Binney St, Room Sw331, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Kieran is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Kieran is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioma, Brain Stem Cancer, Diffuse Midline Glioma H3 K27M-Mutant, and Medulloblastoma.

His clinical research consists of co-authoring 180 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 15 articles in the study of Diffuse Midline Glioma H3 K27M-Mutant.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

44 Binney St, Room Sw331, Boston, MA 02115

Additional Areas of Focus

Dr. Kieran has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma, Ependymoma and ATRT
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma, Ependymoma and ATRT
Enrollment Status: Recruiting
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Thalidomide, Celecoxib, Fenofibric Acid, Etoposide, Cyclophosphamide, Etoposide Phosphate, Cytarabine
Study Phase: Phase 2
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Binimetinib
Study Phase: Phase 2
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine
Study Phase: Phase 2
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Device
Study Phase: Not Applicable
A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors
A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: October 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Enrollment Status: Completed
Publish Date: February 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas
A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas
Enrollment Status: Completed
Publish Date: August 15, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

180 Total Publications

Clinical and Molecular Characteristics of 100 Atypical Teratoid Rhabdoid Tumor Patients from Low- and Middle-Income Countries.
Clinical and Molecular Characteristics of 100 Atypical Teratoid Rhabdoid Tumor Patients from Low- and Middle-Income Countries.
Journal: Cancers
Published: August 09, 2025
Similar Doctors
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Tabitha M. Cooney
Pediatric Hematology Oncology
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Tabitha M. Cooney
Pediatric Hematology Oncology
300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances

Tabitha Cooney is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Cooney is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Brain Stem Cancer, Diffuse Midline Glioma H3 K27M-Mutant, Ganglioglioma, and Glioma.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Mariella G. Filbin
Pediatric Hematology Oncology
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Mariella G. Filbin
Pediatric Hematology Oncology
450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-5042
Languages Spoken:
English
See accepted insurances

Mariella Filbin is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Filbin is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Glioma, Medulloblastoma, Brain Stem Cancer, and Diffuse Midline Glioma H3 K27M-Mutant.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Susan N. Chi
Pediatric Hematology Oncology
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Susan N. Chi
Pediatric Hematology Oncology
44 Binney St, Room Sw 331, 
Boston, MA 
 (0.1 miles away)
617-632-4142
Languages Spoken:
English
See accepted insurances

Susan Chi is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Chi is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Rhabdoid Tumor, Glioma, Medulloblastoma, and Brain Stem Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kieran's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile